This segment focuses on the research, development, and clinical evaluation of novel therapies for severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and complications from COVID-19. The lead product candidate, ATYR1923 (efzofitimod), is a selective modulator of NRP2. Research and development activities include Phase 1b/2a clinical trials for pulmonary sarcoidosis and Phase 3 trials for other ILDs. Technologies employed involve protein-based therapeutics and immunological pathway modulation. The goal is to improve lung function and quality of life for patients with these debilitating conditions. Market positioning is based on addressing unmet medical needs in rare and severe respiratory diseases. Future opportunities include expanding the application of ATYR1923 to other respiratory conditions and potential partnerships for commercialization. Regulatory and clinical aspects involve navigating FDA and international regulatory pathways. Collaborations with Kyorin Pharmaceutical Co., Ltd. support development and commercialization in Japan.

This segment is dedicated to preclinical research and development of novel cancer therapies. The primary focus is on ATYR2810, a fully humanized monoclonal antibody, designed to target and treat various aggressive cancers. Research activities include preclinical studies to evaluate efficacy and safety. The technologies employed involve monoclonal antibody development and cancer immunology. The aim is to develop targeted therapies that can improve outcomes for cancer patients. Market positioning is based on developing innovative cancer treatments with the potential to address unmet needs. Future opportunities include advancing ATYR2810 into clinical trials and exploring combination therapies. Regulatory and clinical aspects involve preclinical studies and preparing for clinical trial submissions. This segment may involve collaborations with research institutions and pharmaceutical companies to accelerate development.